{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:18:33Z","timestamp":1793449113111,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005722","name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Critical Care"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jcrc.2022.154100","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:17:54Z","timestamp":1656548274000},"page":"154100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Serum linezolid concentrations are reduced in critically ill patients with pulmonary infections: A prospective observational study"],"prefix":"10.1016","volume":"71","author":[{"given":"Michael","family":"Zoller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Paal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Greimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kallee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vogeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irlbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Liebchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcrc.2022.154100_bb0005","first-page":"276","article-title":"A new paradigm for treating infections: \u201cgo hard and go home\u201d","volume":"11","author":"Lipman","year":"2009","journal-title":"Crit Care Resusc"},{"key":"10.1016\/j.jcrc.2022.154100_bb0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving Sepsis campaign: international guidelines for Management of Sepsis and Septic Shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"issue":"255\u201371","key":"10.1016\/j.jcrc.2022.154100_bb0015","first-page":"vi","article-title":"Pharmacokinetic changes in critical illness","volume":"22","author":"Boucher","year":"2006","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jcrc.2022.154100_bb0020","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/cid\/ciaa224","article-title":"The effect of renal replacement therapy and antibiotic dose on antibiotic concentrations in critically ill patients: data from the multinational sampling antibiotics in renal replacement therapy study","volume":"72","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2022.154100_bb0030","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","article-title":"Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions","volume":"14","author":"Roberts","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1590\/S1413-86702009000200004","article-title":"Antimicrobial susceptibility of gram-positive bacteria isolated in Brazilian hospitals participating in the SENTRY Program (2005\u20132008)","volume":"13","author":"Gales","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0040","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12879-021-05877-3","article-title":"A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19","volume":"21","author":"Puzniak","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0045","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jcrc.2022.154100_bb0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00134-014-3550-y","article-title":"Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration","volume":"41","author":"De Pascale","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2022.154100_bb0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13054-019-2523-5","article-title":"Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients","volume":"23","author":"Fernandez-Barat","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2022.154100_bb0060","article-title":"Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia","volume":"6","author":"Narayanan","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0065","first-page":"1136","article-title":"Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects","volume":"29","author":"Slatter","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jcrc.2022.154100_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111631","article-title":"In linezolid underexposure, pharmacogenetics matters: the role of CYP3A5","volume":"139","author":"Cheli","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0075","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/11319960-000000000-00000","article-title":"Pharmacological issues of linezolid: an updated critical review","volume":"49","author":"Di Paolo","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcrc.2022.154100_bb0080","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","article-title":"Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study","volume":"18","author":"Zoller","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2022.154100_bb0085","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1128\/AAC.00177-10","article-title":"Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis","volume":"54","author":"Pea","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0090","first-page":"65","article-title":"Evaluation of linezolid pharmacokinetics in critically ill obese patients with severe skin and soft tissue infections","author":"Blackman","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0095","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcrc.2022.154100_bb0100","first-page":"320","article-title":"Linezolid-induced haematological toxicity","volume":"39","author":"Moraza","year":"2015","journal-title":"Farm Hosp"},{"key":"10.1016\/j.jcrc.2022.154100_bb0105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s13054-014-0525-x","article-title":"Therapeutic drug monitoring: linezolid too?","volume":"18","author":"Richards","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2022.154100_bb0110","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bcpt.12797","article-title":"A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients?","volume":"121","author":"Pea","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jcrc.2022.154100_bb0115","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FTD.0000000000000324","article-title":"Variable linezolid exposure in intensive care unit patients-possible role of drug-drug interactions","volume":"38","author":"Topper","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jcrc.2022.154100_bb0120","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00133-20","article-title":"Population pharmacokinetics and dosage optimization of linezolid in patients with liver dysfunction","volume":"64","author":"Zhang","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0125","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1128\/AAC.00356-16","article-title":"Predictors of inadequate linezolid concentrations after standard dosing in critically ill patients","volume":"60","author":"Taubert","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","article-title":"Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study","volume":"24","author":"Kuhn","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2022.154100_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106572","article-title":"Population pharmacokinetics and toxicodynamics of continuously infused linezolid in critically ill patients","author":"Wicha","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcrc.2022.154100_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpba.2018.01.031","article-title":"Simultaneous quantification of cefepime, meropenem, ciprofloxacin, moxifloxacin, linezolid and piperacillin in human serum using an isotope-dilution HPLC-MS\/MS method","volume":"152","author":"Paal","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.jcrc.2022.154100_bb0145","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s00134-012-2682-1","article-title":"The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material","volume":"38","author":"Ferguson","year":"2012","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jcrc.2022.154100_bb0150","first-page":"118","article-title":"Pharmacokinetics and pharmacodynamics of Linezolid in burn patients","volume":"31","author":"Mokline","year":"2018","journal-title":"Ann Burns Fire Disasters"},{"key":"10.1016\/j.jcrc.2022.154100_bb0155","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","article-title":"Dosage regimen and toxicity risk assessment of linezolid in sepsis patients","volume":"96","author":"Dou","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jcrc.2022.154100_bb0160","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/jac\/dks153","article-title":"Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients","volume":"67","author":"Pea","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0165","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/jac\/dkg180","article-title":"Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers","volume":"51","author":"Stalker","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0170","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/ajhp\/zxaa066","article-title":"Pharmacokinetics of linezolid for methicillin-resistant Staphylococcus aureus pneumonia in an adult receiving extracorporeal membrane oxygenation","volume":"77","author":"Nikolos","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jcrc.2022.154100_bb0175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ijantimicag.2013.01.016","article-title":"Pharmacokinetics of linezolid during extracorporeal membrane oxygenation","volume":"41","author":"De Rosa","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcrc.2022.154100_bb0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13054-015-0891-z","article-title":"Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study","volume":"19","author":"Shekar","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.jcrc.2022.154100_bb0185","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1185\/03007990903512057","article-title":"The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid","volume":"26","author":"Stein","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jcrc.2022.154100_bb0190","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0195","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1097\/01.CCM.0000168206.59873.80","article-title":"Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia","volume":"33","author":"Boselli","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jcrc.2022.154100_bb0200","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/jac\/dks022","article-title":"Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia","volume":"67","author":"Boselli","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jcrc.2022.154100_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.2031","article-title":"Pharmacokinetic\/Pharmacodynamic parameters of linezolid in the epithelial lining fluid of patients with Sepsis","author":"Wu","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcrc.2022.154100_bb0210","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/cpt.2412","article-title":"Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail","volume":"110","author":"Lenoir","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcrc.2022.154100_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/v13030413","article-title":"Pharmacogenetics approach for the improvement of COVID-19 treatment","volume":"13","author":"Fricke-Galindo","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jcrc.2022.154100_bb0220","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/jac\/dkx149","article-title":"Optimization of linezolid therapy in the critically ill: the effect of adjusted infusion regimens","volume":"72","author":"Taubert","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944122001290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0883944122001290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:53Z","timestamp":1760125913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0883944122001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":44,"alternative-id":["S0883944122001290"],"URL":"https:\/\/doi.org\/10.1016\/j.jcrc.2022.154100","relation":{},"ISSN":["0883-9441"],"issn-type":[{"value":"0883-9441","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum linezolid concentrations are reduced in critically ill patients with pulmonary infections: A prospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Critical Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcrc.2022.154100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154100"}}